Abstract
Migraine is a potentially debilitating neurologic disorder affecting approximately 12% of the United States population. Sumatriptan manufacturer-provided drug information states that life threatening arrhythmias, including ventricular tachycardia and ventricular fibrillation (VF), have been reported. A literature search revealed only seven reported cases of ventricular arrhythmias immediately after sumatriptan administration. Twenty minutes after a 42 year old female received sumatriptan, her femoral pulses were not palpable and the electrocardiograph (EKG) showed torsades de pointes followed by VF. After defibrillation and one round of cardiopulmonary resuscitation (CPR), the patient regained spontaneous circulation. The patient was eventually discharged home. Despite studies concluding that sumatriptan has minimal effects on coronary arteries, several cases of sumatriptan-associated myocardial infarction have been documented. In addition, a small number of documented cases have reported life threatening arrhythmias and cardiorespiratory arrest after sumatriptan administration.
Keywords: Cardiac arrest, polymorphic ventricular tachycardia, sumatriptan, torsades de pointes, thyrotoxicosis, triptan, ventricular fibrillation.
Current Drug Safety
Title:Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature
Volume: 9 Issue: 3
Author(s): Stanley E. Hill and Kirsten La
Affiliation:
Keywords: Cardiac arrest, polymorphic ventricular tachycardia, sumatriptan, torsades de pointes, thyrotoxicosis, triptan, ventricular fibrillation.
Abstract: Migraine is a potentially debilitating neurologic disorder affecting approximately 12% of the United States population. Sumatriptan manufacturer-provided drug information states that life threatening arrhythmias, including ventricular tachycardia and ventricular fibrillation (VF), have been reported. A literature search revealed only seven reported cases of ventricular arrhythmias immediately after sumatriptan administration. Twenty minutes after a 42 year old female received sumatriptan, her femoral pulses were not palpable and the electrocardiograph (EKG) showed torsades de pointes followed by VF. After defibrillation and one round of cardiopulmonary resuscitation (CPR), the patient regained spontaneous circulation. The patient was eventually discharged home. Despite studies concluding that sumatriptan has minimal effects on coronary arteries, several cases of sumatriptan-associated myocardial infarction have been documented. In addition, a small number of documented cases have reported life threatening arrhythmias and cardiorespiratory arrest after sumatriptan administration.
Export Options
About this article
Cite this article as:
Hill E. Stanley and La Kirsten, Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature, Current Drug Safety 2014; 9 (3) . https://dx.doi.org/10.2174/1574886309666140601210750
DOI https://dx.doi.org/10.2174/1574886309666140601210750 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Current Pharmaceutical Design Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Current Drug Metabolism In-Vitro and In-Vivo Pharmacological Activities with Phytochemical Evaluation of Methanolic Extract of Microcos paniculata Stem Barks
Current Drug Therapy Emerging Therapies for Type 2 Diabetes
Current Drug Therapy Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology Overview and Findings from the Rush Memory and Aging Project
Current Alzheimer Research Research Progress of the UPR Mechanism and its Effect on Improving Foreign Protein Expression
Protein & Peptide Letters Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Stroke Prevention in Patients with Non-valvular Atrial Fibrillation: New Insight in Selection of Rhythm or Rate Control Therapy and Impact of Mean Platelet Volume
Current Pharmaceutical Design Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Galectin-3 and Arterial Stiffness in Patients with Heart Failure: A Pilot Study
Current Vascular Pharmacology Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology Mechanism of Local Anesthetic Drug Action on Voltage-Gated Sodium Channels
Current Pharmaceutical Design Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Editorial (Thematic Issue: The Life Cycle of the Heart Failure Patient)
Current Cardiology Reviews The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design